American Journal of Advanced Drug Delivery Open Access

  • ISSN: 2321-547X
  • Journal h-index: 22
  • Journal CiteScore: 9.36
  • Journal Impact Factor: 5.76
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days

Qian Zhong

Qian Zhong
Stanford University, Stanford, California, United States


Dr. Qian Zhong is currently a postdoctoral associate at the Department of Radiology at Stanford University, California, USA. He received Ph.D degree from the Department of Chemical Engineering and Material Science at Wayne State University, Detroit, Michigan, USA at 2016. His research interests include nanomedicine for cancer chemotherapy and immunotherapy, antimicrobial nanomedicine, dendrimer chemistry, polymer synthesis and blending, pulmonary drug delivery, and nasal/oral inhalation formulation technology. He has published over 32 peer-reviewed publications and conference paper. He served as reviewers, editors or editorial board members for a few journals, including MAYFEB Journal of Material Science, Journal of Drug Delivery, Journal of Applied Pharmaceutical Science, Journal of Food Processing Engineering, Indian Journal of Advances in Chemical Science, and Tropical Journal of Pharmaceutical Research. He is also the member of a few professional societies including American Institute of Chemical Engineers, American Association of Pharmaceutical Science, and Respiratory Drug Delivery, Control Release society. He has published 9 peer-reviewed research articles and had 19 oral/poster presentations in national and international conferences since 2012.

Research Interest

My research mainly focuses on the development of stimuli-responsive dendrimer nanocarriers for targeted delivery of small-molecule therapeutics and biomacromolecule to malignant tumors and infections. (i) Local Delivery of Dendrimer Nanomedicines for Lung Cancer Treatment/Lung Metastasis Prophylaxis -Engineered stimuli-responsive dendrimer-anticancer agent nanoconjugates to achieve cancer tissue targeting, promote intracellular drug delivery to specific organelles, and overcome drug resistance. -Pulmonary administration of the nanoconjugates to increase drug accumulation in lung tumors, while minimize systemic toxicity. ? Validated in vitro/in vivo stimuli responsiveness of dendrimer nanomedicnes. -Evaluated the antitumor activity of the nanoconjugates on a variety of primary lung cancers and metastatic cancers to lungs, systemic and local toxicity, and in vitro/in vivo fate of dendrimer nanoconjugates (i.e. cellular interaction, pharmacokinetics, biodistribution). (ii) Oral Inhalation Formulations of Dendrimeric Nanomedicines for Non-invasive Pulmonary Delivery -Developed portable aerosol formulations of dendrimer-based nanomedicines in metered dose inhaler and dry powder inhaler. -Optimized drug dosing, aerosol performance, and long-shelf stability (iii) Targeted Chemotherapeutic Delivery with Dendrimer Nanocarriers for Cancer Treatment -Designed long-time circulatory dendrimer nanocarriers that target therapeutics to malignant tumors. -Evaluated the antitumor activity and in vivo fate of targeted dendrimer-based nanomedicines (e.g. pharmacokinetics, biodistribution, and toxicity). -The developed drug delivery system are being tested in breast cancer and bone metastasis models. (iv) Stimuli-Responsive Dendrimer Nanocarrier as a Cancer Vaccine Delivery Platform -Engineered enzyme-sensitive dendrimer-peptide nanovaccine for enhanced immune response -Improved tumor inhibition have been validated in two cancer model human papillomavirus-induced cervical cancer and lung metastasis from melanoma